Form 8-K - Current report:
SEC Accession No. 0001104659-24-002631
Filing Date
2024-01-09
Accepted
2024-01-09 17:10:15
Documents
12
Period of Report
2024-01-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm242562d1_8k.htm   iXBRL 8-K 41383
  Complete submission text file 0001104659-24-002631.txt   218082

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA elox-20240109.xsd EX-101.SCH 3024
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE elox-20240109_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elox-20240109_pre.xml EX-101.PRE 22365
6 EXTRACTED XBRL INSTANCE DOCUMENT tm242562d1_8k_htm.xml XML 3230
Mailing Address 480 ARSENAL WAY SUITE 130 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY SUITE 130 WATERTOWN MA 02472 781-577-5300
Eloxx Pharmaceuticals, Inc. (Filer) CIK: 0001035354 (see all company filings)

EIN.: 841368850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31326 | Film No.: 24524057
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)